Allscripts Healthcare Solutions Company Profile (NASDAQ:MDRX)

Allscripts Healthcare Solutions trades on the NASDAQ under the ticker symbol "MDRX."

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) posted its quarterly earnings data on Thursday, May, 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.01. The firm had revenue of $415 million for the quarter, compared to the consensus estimate of $415.20 million. Allscripts Healthcare Solutions had a negative net margin of 2.93% and a positive return on equity of 5.75%. The company's revenue for the quarter was up 20.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.13 earnings per share. View Allscripts Healthcare Solutions' Earnings History.

Allscripts Healthcare Solutions is scheduled to release their next quarterly earnings announcement on Thursday, August, 3rd 2017. View Earnings Estimates for Allscripts Healthcare Solutions.

18 brokers have issued 1 year price targets for Allscripts Healthcare Solutions' shares. Their predictions range from $10.00 to $19.00. On average, they expect Allscripts Healthcare Solutions' stock price to reach $14.50 in the next year. View Analyst Ratings for Allscripts Healthcare Solutions.

Here are some recent quotes from research analysts about Allscripts Healthcare Solutions stock:

• 1. Maxim Group analysts commented, "1Q17 bookings of $286M, up 13.5% y/y, were below our estimate of $302M and consensus of $298M." (5/5/2017)
• 2. According to Zacks Investment Research, "Over the past three months, Allscripts has outperformed the broader industry trend in terms of price movement. However, an unfavorable estimate revision trend indicates looming concerns ahead. An intensifying market competition is a major dampener for Allscripts as large companies like Cerner, compete against Allscripts with a far simpler rationale for their products. Additionally, the Optum partnership is expected to have a cost-heavy impact on the revenues. Allscripts’ products have a long sales cycle which involves decision-making at different managerial levels. On a positive note, Allscripts has been reporting regular contract wins and addition of new domestic and international clients, which is expected to boost bookings in the coming quarters. Furthermore, the growing adoption of Allscripts’ products and services like the Sunrise platform, FollowMyHealth, Touchworks EHR, EPSi and dbMotion will drive market traction." (4/19/2017)
• 3. Citigroup Inc. analysts commented, "We are upgrading MDRX shares to Buy following its recent analyst day. Allscripts provided targets for 2018 - 2020 revenue growth of 6%-8% and EPS growth of 12%-15%, both of which are ahead of our forecasts but approximately in-line with the Street. Allscripts is beginning to show better results as non-recurring revenue has stabilized, recurring revenue grows faster, and the mix continues to shift to recurring revenue, with non EMR solutions seeing faster growth. We believe that if Allscripts can hit these targets investors could see a 20% return on the shares this year from current levels." (3/24/2017)
• 4. Piper Jaffray Companies analysts commented, "We attended Allscripts' Investor Conference yesterday where management discussed its plan to deliver its FY17 guidance and long term growth targets. We believe 6-8% revenue growth and 12-15% EPS growth are achievable, provided the non-recurring revenue has surpassed its decline, and the Platform as a Service model continues to grow. We are tapering our FY18 EPS estimate to be in line with targets while maintaining our 20x EPS valuation, which brings our PT to $14 from $15. Reiterate Neutral." (3/22/2017)
• 5. Cantor Fitzgerald analysts commented, "We reiterate our Neutral rating on Allscripts shares and our 12-month price target remains $13. On Tuesday, March 21, Allscripts hosted an analyst meeting. The company provided good insight into its growth strategy. In our view, the most important points were the strong improvement in client satisfaction scores, details on its CareInMotion population health applications and its payer initiatives. The company provided 3-year CAGR growth targets (2018 to 2020), which were in line with our long-term DCF model assumptions. While the company's fundamentals have improved over the last few years, the shares offer nominal upside to our price target of $13. Our rating remains at Neutral." (3/22/2017)

Allscripts Healthcare Solutions saw a increase in short interest during the month of July. As of July 14th, there was short interest totalling 25,906,388 shares, an increase of 0.4% from the June 30th total of 26,017,206 shares. Based on an average daily volume of 3,148,489 shares, the short-interest ratio is currently 8.2 days. Currently, 14.5% of the shares of the company are short sold.

Some companies that are related to Allscripts Healthcare Solutions include Cotiviti Holdings (COTV), HealthEquity (HQY), Evolent Health (EVH), Omnicell (OMCL), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), NantHealth (NH), Craneware plc (CRW), Simulations Plus (SLP), Tabula Rasa Healthcare (TRHC), Fluidigm Corporation (FLDM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Press Ganey Holdings (PGND).

Allscripts Healthcare Solutions' management team includes the folowing people:

• Michael A. Klayko, Independent Chairman of the Board
• Richard J. Poulton, President
• Paul M. Black, Chief Executive Officer, Director
• Dennis M. Olis, Interim Chief Financial Officer, Principal Accounting Officer
• James R. Hewitt, Executive Vice President, Solutions Development
• Lisa Khorey, Executive Vice President, Chief Client Delivery Officer
• Brian P. Farley, Senior Vice President, General Counsel and Corporate Secretary;
• Mara Glickman Aspinall, Independent Director
• P. Gregory Garrison, Independent Director
• Jonathan J. Judge, Independent Director

Allscripts Healthcare Solutions' stock is owned by a number of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.49%), First National Bank of Omaha (0.12%), CWM LLC (0.11%), Tributary Capital Management LLC (0.06%), Dalton Greiner Hartman Maher & Co. (0.06%) and Meeder Asset Management Inc. (0.04%). Company insiders that own Allscripts Healthcare Solutions stock include Brian Farley, Dennis Olis, James Hewitt, Paul Black and Richard J Poulton. View Institutional Ownership Trends for Allscripts Healthcare Solutions.

Allscripts Healthcare Solutions' stock was sold by a variety of institutional investors in the last quarter, including Boston Advisors LLC, First Quadrant L P CA, Capstone Asset Management Co., Patten & Patten Inc. TN and Meeder Asset Management Inc.. Company insiders that have sold Allscripts Healthcare Solutions stock in the last year include Brian Farley, James Hewitt, Paul Black and Richard J Poulton. View Insider Buying and Selling for Allscripts Healthcare Solutions.

Allscripts Healthcare Solutions' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., CWM LLC, Dalton Greiner Hartman Maher & Co., Parametrica Management Ltd, Aperio Group LLC, ING Groep NV, First Citizens Bank & Trust Co. and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Allscripts Healthcare Solutions.

Shares of Allscripts Healthcare Solutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Allscripts Healthcare Solutions stock can currently be purchased for approximately $12.38.